Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Esophageal Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Feng Wang, Zhengzhou, Henan, China
Contact: Study coordinator (Feng Wang)

Study leads

Feng Wang
Principal Investigator
The First Affiliated Hospital of Zhengzhou University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Diffuse Astrocytoma, IDH-Mutant · Glioblastoma, IDH-wildtype · Brain Metastases, Adult

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beverly Hills, United States · Glendale, United States

Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy

Esophageal Neoplasm Metastatic · Esophageal Cancer Stage IVb

Abroad (travel likely)RecruitingPHASE2

Beijing, China

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

Esophageal Squamous Cell Carcinoma · Unresectable Locally Advanced Esophageal Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Shanghai, China

Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients

Esophageal Cancer

Abroad (travel likely)RecruitingPHASE3

Beijing, China